IBRX Quote, Financials, Valuation and Earnings

Corcept Therapeutics, Inc. has a net margin of -209.83% compared to ImmunityBio, Inc.'s net margin of 9.32%. ImmunityBio, Inc.'s return on equity of -- beat Corcept Therapeutics, Inc.'s return on equity of 16%.

ImmunityBio, Inc. has a consensus price target of $10.40, signalling upside risk potential of 385.98%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $127.20 which suggests that it could grow by 53.9%. Given that ImmunityBio, Inc. has higher upside potential than Corcept Therapeutics, Inc., analysts believe ImmunityBio, Inc. is more attractive than Corcept Therapeutics, Inc..

ImmunityBio, Inc. has a beta of -0.028, which suggesting that the stock is 102.834% less volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.197, suggesting its less volatile than the S&P 500 by 80.287%.

ImmunityBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmunityBio, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.

ImmunityBio, Inc. quarterly revenues are $32.1M, which are smaller than Corcept Therapeutics, Inc. quarterly revenues of $207.6M. ImmunityBio, Inc.'s net income of -$67.3M is lower than Corcept Therapeutics, Inc.'s net income of $19.4M. Notably, ImmunityBio, Inc.'s price-to-earnings ratio is -- while Corcept Therapeutics, Inc.'s PE ratio is 94.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunityBio, Inc. is 22.18x versus 13.33x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Cytokinetics, Inc. has a net margin of -209.83% compared to ImmunityBio, Inc.'s net margin of -15814.98%. ImmunityBio, Inc.'s return on equity of -- beat Cytokinetics, Inc.'s return on equity of --.

ImmunityBio, Inc. has a consensus price target of $10.40, signalling upside risk potential of 385.98%. On the other hand Cytokinetics, Inc. has an analysts' consensus of $85.44 which suggests that it could grow by 35.39%. Given that ImmunityBio, Inc. has higher upside potential than Cytokinetics, Inc., analysts believe ImmunityBio, Inc. is more attractive than Cytokinetics, Inc..

ImmunityBio, Inc. has a beta of -0.028, which suggesting that the stock is 102.834% less volatile than S&P 500. In comparison Cytokinetics, Inc. has a beta of 0.584, suggesting its less volatile than the S&P 500 by 41.614%.

ImmunityBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmunityBio, Inc. pays -- of its earnings as a dividend. Cytokinetics, Inc. pays out -- of its earnings as a dividend.

ImmunityBio, Inc. quarterly revenues are $32.1M, which are larger than Cytokinetics, Inc. quarterly revenues of $1.9M. ImmunityBio, Inc.'s net income of -$67.3M is higher than Cytokinetics, Inc.'s net income of -$306.2M. Notably, ImmunityBio, Inc.'s price-to-earnings ratio is -- while Cytokinetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunityBio, Inc. is 22.18x versus 86.12x for Cytokinetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Moderna, Inc. has a net margin of -209.83% compared to ImmunityBio, Inc.'s net margin of -19.69%. ImmunityBio, Inc.'s return on equity of -- beat Moderna, Inc.'s return on equity of -30.18%.

ImmunityBio, Inc. has a consensus price target of $10.40, signalling upside risk potential of 385.98%. On the other hand Moderna, Inc. has an analysts' consensus of $36.75 which suggests that it could grow by 17.79%. Given that ImmunityBio, Inc. has higher upside potential than Moderna, Inc., analysts believe ImmunityBio, Inc. is more attractive than Moderna, Inc..

ImmunityBio, Inc. has a beta of -0.028, which suggesting that the stock is 102.834% less volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.109, suggesting its more volatile than the S&P 500 by 10.882%.

ImmunityBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmunityBio, Inc. pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

ImmunityBio, Inc. quarterly revenues are $32.1M, which are smaller than Moderna, Inc. quarterly revenues of $1B. ImmunityBio, Inc.'s net income of -$67.3M is higher than Moderna, Inc.'s net income of -$200M. Notably, ImmunityBio, Inc.'s price-to-earnings ratio is -- while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunityBio, Inc. is 22.18x versus 5.41x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Relay Therapeutics, Inc. has a net margin of -209.83% compared to ImmunityBio, Inc.'s net margin of -10395.13%. ImmunityBio, Inc.'s return on equity of -- beat Relay Therapeutics, Inc.'s return on equity of -41.21%.

ImmunityBio, Inc. has a consensus price target of $10.40, signalling upside risk potential of 385.98%. On the other hand Relay Therapeutics, Inc. has an analysts' consensus of $14.60 which suggests that it could grow by 70.56%. Given that ImmunityBio, Inc. has higher upside potential than Relay Therapeutics, Inc., analysts believe ImmunityBio, Inc. is more attractive than Relay Therapeutics, Inc..

ImmunityBio, Inc. has a beta of -0.028, which suggesting that the stock is 102.834% less volatile than S&P 500. In comparison Relay Therapeutics, Inc. has a beta of 1.501, suggesting its more volatile than the S&P 500 by 50.076%.

ImmunityBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Relay Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmunityBio, Inc. pays -- of its earnings as a dividend. Relay Therapeutics, Inc. pays out -- of its earnings as a dividend.

ImmunityBio, Inc. quarterly revenues are $32.1M, which are larger than Relay Therapeutics, Inc. quarterly revenues of --. ImmunityBio, Inc.'s net income of -$67.3M is higher than Relay Therapeutics, Inc.'s net income of -$74.1M. Notably, ImmunityBio, Inc.'s price-to-earnings ratio is -- while Relay Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunityBio, Inc. is 22.18x versus 174.21x for Relay Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.